Neurovive Pharmaceutical AB
Records under this name other than patents Neurovive Pharmaceutical AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Neurovive Pharmaceutical AB
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,040,487 | Cyclosporine emulsion Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,139,613 | Macrocyclic compounds and methods for their production Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,119,853 | Sanglifehrin based compounds Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,271,977 | Sanglifehrin derivatives and methods for their production Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,090,657 | Compound and methods for its production Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,307,389 | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,147,789 | Novel Cell-Permeable Succinate Compounds Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 12,310,940 | Novel Cell-Permeable Succinate Compounds Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,670,175 | Protected succinates for enhancing mitochondrial ATP-production Formerly held Lapsed on the fee record Ended Jun 6, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 6, 2025 | From the USPTO record |
| US 10,857,150 | Use of sanglifehrin macrocyclic analogues as anticancer compounds Formerly held Lapsed on the fee record Ended Dec 8, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 8, 2024 | From the USPTO record |